The Current State of Proteomics in GI Oncology

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2008 Dec 24

PMID 19104933

Citations 4

Authors

Ying Lin

William S Dynan

Jeffrey R Lee

Zhao-Hua Zhu

Robert R Schade

Affiliations

Soon will be listed here.

Abstract

Proteomics refers to the study of the entire set of proteins in a given cell or tissue. With the extensive development of protein separation, mass spectrometry, and bioinformatics technologies, clinical proteomics has shown its potential as a powerful approach for biomarker discovery, particularly in the area of oncology. More than 130 exploratory studies have defined candidate markers in serum, gastrointestinal (GI) fluids, or cancer tissue. In this article, we introduce the commonly adopted proteomic technologies and describe results of a comprehensive review of studies that have applied these technologies to GI oncology, with a particular emphasis on developments in the last 3 years. We discuss reasons why the more than 130 studies to date have had little discernible clinical impact, and we outline steps that may allow proteomics to realize its promise for early detection of disease, monitoring of disease recurrence, and identification of targets for individualized therapy.

Citing Articles

A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.

Sandanayake N, Sinclair J, Andreola F, Chapman M, Xue A, Webster G Br J Cancer. 2011; 105(9):1370-8.

PMID: 21970875 PMC: 3241550. DOI: 10.1038/bjc.2011.376.

Proteomic analysis of endoscopically (endoscopic pancreatic function test) collected gastroduodenal fluid using in-gel tryptic digestion followed by LC-MS/MS.

Paulo J, Lee L, Wu B, Repas K, Banks P, Conwell D Proteomics Clin Appl. 2010; 4(8-9):715-25.

PMID: 21137089 PMC: 3210639. DOI: 10.1002/prca.201000018.

Mass-spectrometry-based clinical proteomics--a review and prospective.

Parker C, Pearson T, Anderson N, Borchers C Analyst. 2010; 135(8):1830-8.

PMID: 20520858 PMC: 2966304. DOI: 10.1039/c0an00105h.

Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer.

Lin Y, Buckhaults P, Lee J, Xiong H, Farrell C, Podolsky R Neoplasia. 2009; 11(9):864-73.

PMID: 19724680 PMC: 2735797. DOI: 10.1593/neo.09542.

References

Yu Y, Chen S, Wang L, Chen W, Guo W, Yan H . Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology. 2005; 68(1):79-86. DOI: 10.1159/000084824. View

Tian R, Wei L, Qin R, Li Y, Du Z, Xia W . Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins. Dig Dis Sci. 2007; 53(1):65-72. DOI: 10.1007/s10620-007-9823-3. View

Scarlett C, Saxby A, Nielsen A, Bell C, Samra J, Hugh T . Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology. 2006; 44(3):658-66. DOI: 10.1002/hep.21294. View

Smith F, Gallagher W, Fox E, Stephens R, Rexhepaj E, Petricoin 3rd E . Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg. 2007; 245(2):259-66. PMC: 1876990. DOI: 10.1097/01.sla.0000245577.68151.bd. View

Azad N, Rasool N, Annunziata C, Minasian L, Whiteley G, Kohn E . Proteomics in clinical trials and practice: present uses and future promise. Mol Cell Proteomics. 2006; 5(10):1819-29. DOI: 10.1074/mcp.R600008-MCP200. View

Chen R, Brentnall T, Pan S, Cooke K, White Moyes K, Lane Z . Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics. 2007; 6(8):1331-42. DOI: 10.1074/mcp.M700072-MCP200. View

Jiang X, Jiang X, Feng S, Tian R, Ye M, Zou H . Development of efficient protein extraction methods for shotgun proteome analysis of formalin-fixed tissues. J Proteome Res. 2007; 6(3):1038-47. DOI: 10.1021/pr0605318. View

Melle C, Ernst G, Scheibner O, Kaufmann R, Schimmel B, Bleul A . Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res. 2007; 6(1):306-15. DOI: 10.1021/pr060439b. View

Song H, Liu Y, Cui J, Zhang L, Dai Z, Feng J . [Proteomic analysis on metastasis-associated proteins of hepatocellular carcinoma tissues]. Zhonghua Gan Zang Bing Za Zhi. 2005; 13(5):331-4. View

10.

Orvisky E, Drake S, Martin B, Abdel-Hamid M, Ressom H, Varghese R . Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics. 2006; 6(9):2895-902. DOI: 10.1002/pmic.200500443. View

11.

Zhao G, Gao C, Song G, Li D, Wang X . [Identification of colorectal cancer using proteomic patterns in serum]. Ai Zheng. 2004; 23(6):614-8. View

12.

Rodriguez-Pineiro A, Rodriguez-Berrocal F, Paez de la Cadena M . Improvements in the search for potential biomarkers by proteomics: application of principal component and discriminant analyses for two-dimensional maps evaluation. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 849(1-2):251-60. DOI: 10.1016/j.jchromb.2006.09.021. View

13.

Cui J, Liu Y, Zhou H, Kang X, Huang C, He Y . Screening serum hepatocellular carcinoma-associated proteins by SELDI-based protein spectrum analysis. World J Gastroenterol. 2008; 14(8):1257-62. PMC: 2690676. DOI: 10.3748/wjg.14.1257. View

14.

Ryu J, Kim H, Lee Y, Myong N, Hwang C, Lee G . The proteomics approach to find biomarkers in gastric cancer. J Korean Med Sci. 2003; 18(4):505-9. PMC: 3055082. DOI: 10.3346/jkms.2003.18.4.505. View

15.

Lu Z, Hu L, Evers S, Chen J, Shen Y . Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics. 2004; 4(12):3975-88. DOI: 10.1002/pmic.200300863. View

16.

Hayashida Y, Honda K, Osaka Y, Hara T, Umaki T, Tsuchida A . Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res. 2005; 11(22):8042-7. DOI: 10.1158/1078-0432.CCR-05-0656. View

17.

Zhu X, Zhang W, Li C, Xu Y, Liang W, Tien P . New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J Gastroenterol. 2004; 10(16):2327-9. PMC: 4576282. DOI: 10.3748/wjg.v10.i16.2327. View

18.

Gulmann C, Sheehan K, Kay E, Liotta L, Petricoin 3rd E . Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol. 2006; 208(5):595-606. DOI: 10.1002/path.1958. View

19.

Meuwis M, Fillet M, Geurts P, de Seny D, Lutteri L, Chapelle J . Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007; 73(9):1422-33. DOI: 10.1016/j.bcp.2006.12.019. View

20.

Ebert M, Kruger S, Fogeron M, Lamer S, Chen J, Pross M . Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics. 2005; 5(6):1693-704. DOI: 10.1002/pmic.200401030. View